|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM365921890 |
| 003 |
DE-627 |
| 005 |
20240410232336.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231227s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109870
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1371.xml
|
| 035 |
|
|
|a (DE-627)NLM365921890
|
| 035 |
|
|
|a (NLM)38101497
|
| 035 |
|
|
|a (PII)S1521-6616(23)00634-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Asplund Högelin, Klara
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a B cell activating factor levels are linked to distinct B cell markers in multiple sclerosis and following B cell depletion and repopulation
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.01.2024
|
| 500 |
|
|
|a Date Revised 10.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Recent studies have highlighted the important role of B cells in the pathogenesis of multiple sclerosis (MS). B cell activating factor (BAFF) and A proliferation inducing ligand (APRIL) play a major role in B cell survival and homeostasis. Here, we studied the association of BAFF and APRIL with B cell immune markers in MS and following B cell depletion and repopulation. We found that BAFF but not APRIL was significantly higher in plasma in untreated MS compared to controls. BAFF increased after rituximab treatment and decreased again during repopulation displaying an inverse correlation with B cell numbers, and more specifically switched memory B cell numbers. Cerebrospinal fluid BAFF inversely correlated with IgG index. BAFF displayed an inverse association to anti-EBV-CA antibodies. In summary, our study identified immune cells and factors that might regulate or be regulated by BAFF and APRIL levels in MS, and during B cell depletion and repopulation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a APRIL
|
| 650 |
|
4 |
|a B cells
|
| 650 |
|
4 |
|a BAFF
|
| 650 |
|
4 |
|a EBV
|
| 650 |
|
4 |
|a Multiple sclerosis
|
| 650 |
|
4 |
|a Rituximab
|
| 650 |
|
7 |
|a B-Cell Activating Factor
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor Ligand Superfamily Member 13
|2 NLM
|
| 650 |
|
7 |
|a Rituximab
|2 NLM
|
| 650 |
|
7 |
|a 4F4X42SYQ6
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-4
|2 NLM
|
| 650 |
|
7 |
|a 207137-56-2
|2 NLM
|
| 700 |
1 |
|
|a Isac, Beshoy
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Khademi, Mohsen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Al Nimer, Faiez
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 258(2024) vom: 07. Jan., Seite 109870
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:258
|g year:2024
|g day:07
|g month:01
|g pages:109870
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109870
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 258
|j 2024
|b 07
|c 01
|h 109870
|